Chris Schott

“I just wanted to just touch a little bit more on the duration of some of these promotions. Are these initiatives we should assume continue until macro gets better, or is this more about the competitive dynamics you're facing with these new launches and as that competitive landscape normalizes?”

“I think on slide 15, you highlighted invested capital has been split, kind of two-thirds approved. one-third development stage over time. I guess as royalty has grown, you've built out a broader team.”

“Your line is open. uh thank you so much uh so first one's just on ad tab you know seems like another good quarter for the product just elaborate a bit more on the trends that you're seeing what's driving the strong uptake and how big you think that product can get over time and second question is just on parasiticides…”

“I know it's early, but can you just elaborate a bit more on the Medicare obesity rollout and any learnings and surprises there thus far?”

“First, I wanted to dig into the $1.5 billion increase in the non-COVID guidance. Can you just comment on how much of this is coming from Eloquist versus the rest of the business?”